Comment on Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't

Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't

When biotech investors talk about the future of DNA sequencing, they inevitably focus on industry leader Illumina (NASDAQ: ILMN). But when biotech researchers talk about the future of DNA sequencing, the conversation almost always centers on privately held Oxford Nanopore Technologies, which is developing a new approach to reading genetic code called nanopore sequencing.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News